Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Cotadutide

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 68
  • Status: Phase 2 Clinical
  • What does this mean?
  • Molecular Structure: MW: ~4,046 Da | Class: GLP-1R/GcgR dual peptide agonist | Route: Daily SC injection

About Cotadutide

Cotadutide (MEDI0382) is AstraZeneca/MedImmune's once-daily injectable dual agonist targeting GLP-1 and glucagon receptors. Phase 2b clinical trials in adults with overweight/obesity and type 2 diabetes demonstrated body weight reductions up to 11% versus placebo over 54 weeks, alongside significant reductions in alanine aminotransferase (ALT, −35% vs placebo) and liver fat (MRI-PDFF reduction) — key NASH biomarkers. In a dedicated NASH-focused Phase 2 trial, cotadutide produced both histological improvement in liver steatosis and reduction in fibrosis markers, making it one of the earliest dual agonists with published NASH biopsy data. The compound employs a balanced GLP-1:glucagon pharmacology (approximately 1:1 receptor potency), providing additive hepatic fat oxidation via glucagon signaling on top of GLP-1-mediated insulin sensitization and appetite reduction. Development has been deprioritized by AstraZeneca relative to its broader pipeline, but cotadutide remains scientifically important as a mechanistic benchmark for the GLP-1/glucagon dual-agonist class. Adverse events mirror GLP-1 class: nausea, vomiting, and injection site reactions at therapeutic doses. No major cardiovascular safety signals identified in Phase 2. Its once-daily formulation is a differentiator from the emerging once-weekly competition.

Clinical Focus

GLP-1/Glucagon Dual Agonist — NASH & Type 2 Diabetes

Archival Aliases

MEDI0382

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: ~4,046 Da | Class: GLP-1R/GcgR dual peptide agonist | Route: Daily SC injection
Primary Pathway Metabolic & Weight Loss
Research Phase Phase 2 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] pubmed.ncbi.nlm.nih.gov
[REF 3] clinicaltrials.gov

Data Verified: 2026-04-22

Synergistic Matrix